Zhitong Financial APP learned that on December 12, East Star Medical (301290.SZ) said that the company's new generation of electric endoscopic stapler products had obtained the medical device registration certificate and production license, achieved mass production, and had begun to promote to the domestic market. Overseas sales revenue has increased significantly over the previous year, and the company has not yet planned to set up factories overseas.
On how to face the two-vote system and collection, the company said that the implementation of the "two-vote system" shortens the circulation link and makes the company's ex-factory price close to the terminal hospital sales price, without considering other factors such as "volume purchase". The company's ex-factory price will increase significantly, and the company will actively develop terminal hospital channels to ensure sales volume and finally achieve sales revenue growth.
The company's core product mirror stapler has high technical requirements. At present, the domestic market is mainly occupied by foreign-funded enterprises, while local enterprises mainly focus on the middle and low-end price market. The use of stapler products requires surgical qualification, so the final user of the company's stapler products is the hospital.The key to the realization of "price for quantity" after winning the bid lies in the layout of the terminal hospital channel.Aiming at the key development areas, the company has chosen to cooperate with local dealers with strong strength and layout in advance, and has achieved good results through internal sales team building and training, hospital visits, organizing academic conferences and so on.
In terms of overseas business, in 2021, with the gradual recovery of elective surgery abroad, the demand for stapler in Brazil, Iran, Turkey and other countries increased, while the company actively opened up other overseas markets, so overseas sales revenue increased significantly compared with the previous year. From January to June 2022, the company's overseas market sales accounted for a further increase.At present, the company has no plans to set up factories overseas.
With regard to its views on the future development of the industry, the company said that with stricter supervision, the competitive advantage of head enterprises has been further highlighted; minimally invasive surgery has become increasingly popular, and the demand for high-value endoscopic staplers has continued to improve; industry concentration has been further enhanced. Domestic high-end brands achieve import substitution; from the development path, platform companies will become a trend.